Why IDEX (IEX) Is Getting Attention Today

IDEX (IEX) moved after a Q2 earnings beat and a lift to full year guidance, a combination that put fresh attention on how its core segments, especially Health & Science Technologies, are performing.

The stronger Q2 showing comes on top of an already upbeat run for IDEX, with a year to date share price return of 30.8% and a 1 year total shareholder return of 47.4% indicating that investors have been steadily pricing in better execution. Recent moves, including the latest earnings beat and a reaffirmed quarterly dividend of US$0.73, support a view of building momentum rather than a short term spike around a single quarter.

Scan how IDEX compares with other industrials showing strong execution and earnings momentum in our curated list of list of solid balance sheet and fundamentals (25 results)

After a 1 year total return of 47.4% and a fresh push higher on the Q2 beat, the real puzzle is whether IDEX still offers meaningful upside or if most of the repricing is already in the rearview.

Most Popular Narrative: 8% Undervalued

IDEX closed at $234.29, while the most followed narrative framework pegs fair value at about $255.93. The current debate centers on whether its higher value segments and capital plans justify that gap using an 8.65% discount rate.

Record company backlog of more than US$1b with 28% organic order growth in Q2 2026 and multi quarter visibility in HST and parts of FMT, including future dated data center bookings that extend into 2027, provides a pipeline that can support revenue and cash flow growth beyond what is already recognised.

See why 8 investors see IDEX as 8% undervalued.

Result: Fair Value of $255.93 (UNDERVALUED)

Still, any reversal in the currently strong order trends or a prolonged drag from legacy segments could challenge the IDEX undervaluation story and could rein in expectations.

Find out about the key risks to this IDEX narrative.

Another View: What IDEX’s P/E Is Telling You

The story looks different once price is compared with earnings. IDEX trades on a P/E of 33.2x, while peers average 31.6x and the fair ratio sits at 23.4x. That premium can signal confidence, but it also raises the risk that any disappointment bites harder. Which story do you trust more: the cash flow model or the earnings multiple?

See what the numbers say about this price in our valuation breakdown See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If the mixed signals on IDEX have you torn, move quickly from headline takes to your own verdict by reviewing the full breakdown in 3 key rewards.

Looking for more investment ideas beyond IDEX?

If IDEX has you thinking harder about where you put your capital next, consider exploring a broader opportunity set instead of stopping at a single ticker.

• Target steady compounding potential by scanning companies that consistently return cash to shareholders through 8 dividend fortresses.
• Hunt for mispriced quality by screening for businesses that pair robust fundamentals with appealing valuations using 20 high quality undiscovered gems.
• Protect your downside first by focusing on resilient balance sheets and sturdy financial profiles in our curated 31 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com